The global inhalation CDMO industry is expected to expand at a CAGR of 5.7% in the forecast period 2024 to 2034. The market value is projected to increase from US$ 8,639.1 million in 2024 to US$ 14,863.6 million in 2034.
| Attributes | Key Insights |
|---|---|
| Base Value, 2023 | US$ 8,144.2 million |
| Estimated Global Inhalation CDMO Market Size (2024E) | US$ 8,639.1 million |
| Forecast Inhalation CDMO Market Value (2034F) | US$ 14,863.6 million |
| Value-based CAGR (2024 to 2034) | 5.7% |
The pharmaceutical landscape is undergoing a transformative phase marked by continual innovations in inhalation drug delivery systems, constituting a pivotal driver for the contract development and manufacturing organization (CDMO) market. This evolution encompasses a spectrum of advanced technologies, emphasizing dry powder inhalers (DPIs), metered-dose inhalers (MDIs), and nebulizers.
As respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD) become increasingly prevalent, the demand for efficacious and patient-friendly inhalation therapies escalates. Consequently, pharmaceutical companies are propelled to seek the expertise of specialized CDMOs to navigate the intricacies of these evolving delivery systems.
Formulation development, analytical testing, process optimization, and the production of inhalable medicinal products are the services provided by inhalation CDMOs. They could also help patients navigate the legal and regulatory procedures for developing respiratory drugs.
The expansion of the inhalation CDMO market is facilitated by advancements in inhalation technology, including the creation of unique medication formulations and inventive inhaler devices. Companies in this industry constantly invest in research & development to be on the cutting edge of technological advancements.
The inhalation CDMO market is expanding internationally, with firms offering their services to customers in several geographical areas. Pharmaceutical firms and inhalation CDMOs are increasingly forming partnerships and collaborations to pool resources and expertise.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global inhalation CDMO market recorded a historical CAGR of 4.0% from 2019 to 2023. The increasing prevalence of asthma and COPD drives the incidence of associated respiratory diseases.
In recent years, this has led to a surging demand for efficient respiratory care, including using respiratory inhaler devices. Healthcare professionals are increasingly inclined to adopt inhaler devices to deliver drugs directly to patients' respiratory tracts to ensure minimal wastage of drugs and to increase their efficacy.
The inhalation CDMO market experienced a notable impact from the escalating prevalence of asthma and chronic obstructive pulmonary disease (COPD). The rising incidence of these respiratory conditions has propelled the demand for inhaler devices, becoming a central driver in shaping the market dynamics.
The increasing prevalence of asthma and COPD has led to a growing patient population requiring long-term management and treatment. As a result, there is a heightened need for effective and convenient drug delivery systems, with inhaler devices emerging as a cornerstone in the therapeutic arsenal for these respiratory disorders.
The adoption of newly launched nebulizers with quick drug delivery inhalers would aid demand. In addition, a top-end technological assessment with greater accuracy is gaining traction among the population, further spurring revenue growth for the market.
The relentless pace of technological advancement is a driving force fueling the demand for respiratory inhaler devices and shaping the landscape of the respiratory healthcare market. Technical assessment plays a pivotal role in enhancing the capabilities and functionalities of inhaler devices.
The symbiotic relationship between technology and respiratory care drives the market toward innovative solutions. These would help offer improved patient outcomes, increased treatment adherence, and enhanced disease management.
Principal Consultant
The table below shows the estimated growth rates of the top five countries. China, Japan, and Spain are set to record higher CAGRs of 10.8%, 4.9%, and 3.8%, respectively, through 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| United States | 2.6% |
| China | 10.8% |
| Japan | 4.9% |
| Germany | 2.3% |
| Spain | 3.8% |
The United States dominated the global market and held a 33.1% market share in 2023. The United States is expected to exhibit a CAGR of 2.6% throughout the forecast period, driven by factors like:
The high prevalence of respiratory disorders such as asthma and COPD in the United States is a significant driver for the inhalation CDMO market. The demand for innovative inhalation therapies is surging, ultimately driving the growth of CDMOs in the United States.
In 2023, China held a dominant share of 7.7% in East Asia’s market. The market is expected to surge with a CAGR of 10.8% from 2024 to 2034. Some of the key drivers/trends include:
China faces a rising prevalence of respiratory disorders, including air pollution-related issues and an increasing number of smokers. This creates a substantial demand for advanced inhalation therapies, presenting an opportunity for CDMOs to cater to the growing healthcare needs in China.
China's pharmaceutical market is rapidly expanding, driven by a rising aging population, increased healthcare awareness, and high disposable income. This growth creates opportunities for CDMOs to collaborate with local and international pharmaceutical companies seeking inhalation drug development services.
Germany is expected to surge at a CAGR of 2.3% during the forecast period. This can be attributed to factors like:
Germany is a pharmaceutical hub with a strong emphasis on research and development activities. The country's well-established pharmaceutical industry demands specialized CDMOs, particularly those offering inhalation drug development expertise.
Germany's central location in Europe is a strategic base for companies that serve Europe’s pharmaceutical market. Inhalation CDMOs can leverage this location to establish a presence and cater to the diverse needs of the pharmaceutical industry.
Japan is set to surge at a CAGR of 4.9% between 2024 and 2034. Factors driving the market growth include:
In Japan, there is a high frequency of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD), which drives up demand for inhalation treatments. As a result, inhalation CDMOs now have the chance to work with pharmaceutical firms to develop and produce respiratory medicinal products.
Japan has a solid pharmaceutical regulation system in place. Operating in Japan, inhalation CDMOs must navigate and abide by the rules established by the Pharmaceuticals and Medical Devices Agency (PMDA). Comprehending and obeying these rules is essential to developing and effectively launching new products in the market.
Japan is renowned for its technological breakthroughs. The country’s inventive research and development in inhalation medication delivery methods and technologies can benefit inhalation CDMOs operating nationwide. Being at the forefront of these developments enables companies to provide their clients with state-of-the-art solutions.
Over the forecast period, demand for inhalation CDMO in Spain is expected to rise at a CAGR of 3.8%. This growth projection can be attributed to several key factors:
Spain is a vital country in the global pharmaceuticals market. Spain-based inhalation CDMOs can expand their offerings to serve clients abroad or collaborate with multinational pharmaceutical firms. Incorporating this integration with the global market can yield supplementary growth prospects.
The aging population of Spain is driving up demand for healthcare services and pushing the inhalation CDMO market. The elderly are more likely to suffer from respiratory disorders, which makes effective inhalation therapy necessary. By creating specialized respiratory therapies, inhalation CDMOs can help satisfy these healthcare demands.
For inhalation CDMOs, it is crucial to consider Spain’s market trends and cultural preferences. Inhalable medicine products can succeed more in Spain’s market if their formulations and delivery methods are customized to suit regional tastes and medical standards.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The below section shows the commercial segment dominating by scale of operation. It is expected to surge at a CAGR of 6.3% by 2034. Based on product, the API segment is anticipated to rise at a 6.0% CAGR by 2034.
| Segment | Value CAGR (2024 to 2034) |
|---|---|
| Commercial (Scale of Operation) | 6.3% |
| Formulation Development (Services) | 4.5% |
| API (Product) | 6.0% |
| Medium (Company Size) | 3.6% |
Collaborations and acquisitions are common growth strategies that leading companies employ in the inhalation CDMO market. They aim to enhance their capabilities, expand their service offerings, and stay competitive in the dynamic landscape.
For instance
| Attribute | Details |
|---|---|
| Estimated Market Size (2024) | US$ 8,639.1 million |
| Forecast Market Value (2034) | US$ 14,863.6 million |
| Anticipated Growth Rate (2024 to 2034) | 5.7% |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | US$ million for Value |
| Key Regions Covered | North America; Latin America; East Asia; South Asia and Pacific; Western Europe; Eastern Europe; Middle East and Africa |
| Key Countries Covered | United States, Canada, Mexico, Brazil, Chile, China, Japan, South Korea, Germany, France, Spain, Italy, BENELUX, Nordic Countries, United Kingdom, BENELUX, Poland, Hungary, Romania, India, ASEAN Countries, Australia and New Zealand, GCC Countries, South Africa, and Türkiye |
| Key Market Segments Covered | Service, Product, Company Size, Scale of Operation, and Region |
| Key Companies Profiled | Recipharm AB; AptarGroup, Inc.; Hovione; Vectura Group Ltd; Nemera; Kindeva; H&T Presspart; Sanner GmbH; Stevanato Group; Medspray; ICONOVO AB; Lonza; Gerresheimer AG; Catalent; Patheon N.V. (Thermo Fisher Scientific, Inc.); Lubrizol Life Science; Enteris BioPharma; Cambrex Corporation; INKE; Piramal Pharma Limited; Lupin |
| Report Coverage | Market Forecast, Competition Intelligence, Drivers, Restraints, Opportunities, Trends Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
The global market was valued at US$ 8,144.2 million in 2023.
The market is set to reach a valuation of US$ 14,863.6 million by 2034.
Demand for inhalation CDMO increased at a 5.7% CAGR from 2019 to 2023.
The global market is projected to reach US$ 8,639.1 million by 2024.
The United States accounted for a 33.1% share of the global market in 2023.
Germany held around 2.3% market share in 2023.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Development/Innovation Trends 4. Value-Added Insights 4.1. Service Adoption / Usage Analysis, By 4.2. Disease Epidemiology, By Key Countries 4.3. Regulatory Scenario 4.3.1. Regulatory Frameworks in United States 4.3.2. Regulatory Frameworks in Canada 4.3.3. Regulatory Frameworks in Europe 4.3.4. Regulatory Frameworks in China 4.3.5. Regulatory Frameworks in Japan 4.3.6. Regulatory Frameworks in India 4.4. Overview of CRO and CDMO Services 4.5. Role of Contract Service Providers 4.6. Overview of CDMO with a Wide Array of Dosage Form Capabilities 4.7. PESTLE Analysis 4.8. Pharma Services Supply Chain Analysis 4.9. Value Chain Analysis 4.10. Sustainability Analysis and its Implications on Propellant Market Dynamics 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global Healthcare Expenditure 5.1.2. R&D Funding Outlook, By Region 5.1.3. R&D Funding Outlook, By Country 5.1.4. Global API CDMO Market Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Growing Prevalence of Respiratory Diseases 5.2.2. Advancements in Inhalation Technology 5.2.3. Increasing Focus on Personalized Medicine 5.2.4. Rising Demand for Generic and Biosimilar Inhalation Products 5.2.5. Regulatory Changes and Compliance Requirements 5.2.6. Increasing Outsourcing of Inhalation Product Development 5.2.7. Globalization of Pharmaceutical Supply Chains 5.2.8. Emerging Markets and Untapped Opportunities 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. Global Market Demand (in Value or Size in US$ million) Analysis 2019 to 2023 and Forecast, 2024 to 2034 6.1. Historical Market Value (US$ million) Analysis, 2019 to 2023 6.2. Current and Future Market Value (US$ million) Projections, 2024 to 2034 6.2.1. Y-o-Y Growth Trend Analysis 6.2.2. Absolute $ Opportunity Analysis 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Services 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ million) Analysis By Services, 2019 to 2023 7.3. Current and Future Market Size (US$ million) Analysis and Forecast By Services, 2024 to 2034 7.3.1. Formulation Development 7.3.2. Device Development and Manufacturing 7.3.3. Clinical Manufacturing 7.3.4. Scale-up and Tech Transfer 7.3.5. Quality Control and Quality Assurance 7.3.6. Technology and Innovation 7.3.7. Regulatory Assistance 7.3.8. Analytical Services 7.4. Market Attractiveness Analysis By Services 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ million) By Product, 2019 to 2023 8.3. Current and Future Market Size (US$ million) Analysis and Forecast By Product, 2024 to 2034 8.3.1. API 8.3.1.1. API Substrate 8.3.1.2. Large Molecule 8.3.1.3. Small Molecule 8.3.2. Inhalation Platform 8.3.2.1. Dry Powder Inhalers (DPIs) 8.3.2.2. Metered Dose Inhalers (MDIs) 8.3.2.3. Soft Mist Inhaler 8.4. Market Attractiveness Analysis By Product 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Company Size 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ million) By Company Size, 2019 to 2023 9.3. Current and Future Market Size (US$ million) Analysis and Forecast By Company Size, 2024 to 2034 9.3.1. Large 9.3.2. Medium 9.3.3. Small 9.4. Market Attractiveness Analysis By Company Size 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Scale of Operation 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ million) By Scale of Operation, 2019 to 2023 10.3. Current and Future Market Size (US$ million) Analysis and Forecast By Scale of Operation, 2024 to 2034 10.3.1. Preclinical 10.3.2. Clinical 10.3.3. Commercial 10.4. Market Attractiveness Analysis By Scale of Operation 11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ million) Trend Analysis by Region, 2019 to 2023 11.3. Current and Future Market Size (US$ million) Analysis and Forecast by Region, 2024 to 2034 11.3.1. North America 11.3.2. Latin America 11.3.3. East Asia 11.3.4. South Asia & Pacific 11.3.5. Western Europe 11.3.6. Eastern Europe 11.3.7. Middle East and Africa 11.4. Market Attractiveness Analysis by Region 12. North America Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034 12.1. Introduction 12.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023 12.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034 12.3.1. By Country 12.3.1.1. United States 12.3.1.2. Canada 12.3.2. By Services 12.3.3. By Product 12.3.4. By Company Size 12.3.5. By Scale of Operation 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Services 12.4.3. By Product 12.4.4. By Company Size 12.4.5. By Scale of Operation 12.5. Market Trends 12.6. Drivers & Restraints Impact Analysis 12.7. Country-Wise Analysis 12.7.1. United States Market Analysis 12.7.1.1. Introduction 12.7.1.2. Market Analysis and Forecast by Market Taxonomy 12.7.1.2.1. By Services 12.7.1.2.2. By Product 12.7.1.2.3. By Company Size 12.7.1.2.4. By Scale of Operation 12.7.2. Canada Market Analysis 12.7.2.1. Introduction 12.7.2.2. Market Analysis and Forecast by Market Taxonomy 12.7.2.2.1. By Services 12.7.2.2.2. By Product 12.7.2.2.3. By Company Size 12.7.2.2.4. By Scale of Operation 12.7.3. Mexico Market Analysis 12.7.3.1. Introduction 12.7.3.2. Market Analysis and Forecast by Market Taxonomy 12.7.3.2.1. By Services 12.7.3.2.2. By Product 12.7.3.2.3. By Company Size 12.7.3.2.4. By Scale of Operation 13. Latin America Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034 13.1. Introduction 13.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023 13.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034 13.3.1. By Country 13.3.1.1. Brazil 13.3.1.2. Chile 13.3.1.3. Rest of Latin America 13.3.2. By Services 13.3.3. By Product 13.3.4. By Company Size 13.3.5. By Scale of Operation 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Services 13.4.3. By Product 13.4.4. By Company Size 13.4.5. By Scale of Operation 13.5. Market Trends 13.6. Drivers & Restraints Impact Analysis 13.7. Country-Wise Analysis 13.7.1. Brazil Market Analysis 13.7.1.1. Introduction 13.7.1.2. Market Analysis and Forecast by Market Taxonomy 13.7.1.2.1. By Services 13.7.1.2.2. By Product 13.7.1.2.3. By Company Size 13.7.1.2.4. By Scale of Operation 13.7.2. Chile Market Analysis 13.7.2.1. Introduction 13.7.2.2. Market Analysis and Forecast by Market Taxonomy 13.7.2.2.1. By Services 13.7.2.2.2. By Product 13.7.2.2.3. By Company Size 13.7.2.2.4. By Scale of Operation 14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034 14.1. Introduction 14.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023 14.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034 14.3.1. By Country 14.3.1.1. China 14.3.1.2. Japan 14.3.1.3. South Korea 14.3.2. By Services 14.3.3. By Product 14.3.4. By Company Size 14.3.5. By Scale of Operation 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Services 14.4.3. By Product 14.4.4. By Company Size 14.4.5. By Scale of Operation 14.5. Market Trends 14.6. Drivers & Restraints Impact Analysis 14.7. Country-Wise Analysis 14.7.1. China Market Analysis 14.7.1.1. Introduction 14.7.1.2. Market Analysis and Forecast by Market Taxonomy 14.7.1.2.1. By Services 14.7.1.2.2. By Product 14.7.1.2.3. By Company Size 14.7.1.2.4. By Scale of Operation 14.7.2. Japan Market Analysis 14.7.2.1. Introduction 14.7.2.2. Market Analysis and Forecast by Market Taxonomy 14.7.2.2.1. By Services 14.7.2.2.2. By Product 14.7.2.2.3. By Company Size 14.7.2.2.4. By Scale of Operation 14.7.3. South Korea Market Analysis 14.7.3.1. Introduction 14.7.3.2. Market Analysis and Forecast by Market Taxonomy 14.7.3.2.1. By Services 14.7.3.2.2. By Product 14.7.3.2.3. By Company Size 14.7.3.2.4. By Scale of Operation 15. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034 15.1. Introduction 15.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023 15.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034 15.3.1. By Country 15.3.1.1. India 15.3.1.2. ASEAN Countries 15.3.1.3. Australia & New Zealand 15.3.1.4. Rest of South Asia 15.3.2. By Services 15.3.3. By Product 15.3.4. By Company Size 15.3.5. By Scale of Operation 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Services 15.4.3. By Product 15.4.4. By Company Size 15.4.5. By Scale of Operation 15.5. Market Trends 15.6. Drivers & Restraints Impact Analysis 15.7. Country-Wise Analysis 15.7.1. India Market Analysis 15.7.1.1. Introduction 15.7.1.2. Market Analysis and Forecast by Market Taxonomy 15.7.1.2.1. By Services 15.7.1.2.2. By Product 15.7.1.2.3. By Company Size 15.7.1.2.4. By Scale of Operation 15.7.2. ASEAN Countries Market Analysis 15.7.2.1. Introduction 15.7.2.2. Market Analysis and Forecast by Market Taxonomy 15.7.2.2.1. By Services 15.7.2.2.2. By Product 15.7.2.2.3. By Company Size 15.7.2.2.4. By Scale of Operation 15.7.3. Australia & New Zealand Market Analysis 15.7.3.1. Introduction 15.7.3.2. Market Analysis and Forecast by Market Taxonomy 15.7.3.2.1. By Services 15.7.3.2.2. By Product 15.7.3.2.3. By Company Size 15.7.3.2.4. By Scale of Operation 16. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034 16.1. Introduction 16.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023 16.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034 16.3.1. By Country 16.3.1.1. Germany 16.3.1.2. France 16.3.1.3. Spain 16.3.1.4. Italy 16.3.1.5. BENELUX 16.3.1.6. Nordic Countries 16.3.1.7. United Kingdom 16.3.1.8. Rest of Western Europe 16.3.2. By Services 16.3.3. By Product 16.3.4. By Company Size 16.3.5. By Scale of Operation 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Services 16.4.3. By Product 16.4.4. By Company Size 16.4.5. By Scale of Operation 16.5. Market Trends 16.6. Drivers & Restraints Impact Analysis 16.7. Country-Wise Analysis 16.7.1. Germany Market Analysis 16.7.1.1. Introduction 16.7.1.2. Market Analysis and Forecast by Market Taxonomy 16.7.1.2.1. By Services 16.7.1.2.2. By Product 16.7.1.2.3. By Company Size 16.7.1.2.4. By Scale of Operation 16.7.2. France Market Analysis 16.7.2.1. Introduction 16.7.2.2. Market Analysis and Forecast by Market Taxonomy 16.7.2.2.1. By Services 16.7.2.2.2. By Product 16.7.2.2.3. By Company Size 16.7.2.2.4. By Scale of Operation 16.7.3. Spain Market Analysis 16.7.3.1. Introduction 16.7.3.2. Market Analysis and Forecast by Market Taxonomy 16.7.3.2.1. By Services 16.7.3.2.2. By Product 16.7.3.2.3. By Company Size 16.7.3.2.4. By Scale of Operation 16.7.4. Italy Republic Market Analysis 16.7.4.1. Introduction 16.7.4.2. Market Analysis and Forecast by Market Taxonomy 16.7.4.2.1. By Services 16.7.4.2.2. By Product 16.7.4.2.3. By Company Size 16.7.4.2.4. By Scale of Operation 16.7.5. BENELUX Republic Market Analysis 16.7.5.1. Introduction 16.7.5.2. Market Analysis and Forecast by Market Taxonomy 16.7.5.2.1. By Services 16.7.5.2.2. By Product 16.7.5.2.3. By Company Size 16.7.5.2.4. By Scale of Operation 16.7.6. Nordic Countries Market Analysis 16.7.6.1. Introduction 16.7.6.2. Market Analysis and Forecast by Market Taxonomy 16.7.6.2.1. By Services 16.7.6.2.2. By Product 16.7.6.2.3. By Company Size 16.7.6.2.4. By Scale of Operation 16.7.7. United Kingdom Market Analysis 16.7.7.1. Introduction 16.7.7.2. Market Analysis and Forecast by Market Taxonomy 16.7.7.2.1. By Services 16.7.7.2.2. By Product 16.7.7.2.3. By Company Size 16.7.7.2.4. By Scale of Operation 17. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034 17.1. Introduction 17.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023 17.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034 17.3.1. By Country 17.3.1.1. Poland 17.3.1.2. Hungary 17.3.1.3. Russia 17.3.1.4. Rest of Eastern Europe 17.3.2. By Services 17.3.3. By Product 17.3.4. By Company Size 17.3.5. By Scale of Operation 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Services 17.4.3. By Product 17.4.4. By Company Size 17.4.5. By Scale of Operation 17.5. Market Trends 17.6. Drivers & Restraints Impact Analysis 17.7. Country-Wise Analysis 17.7.1. Poland Market Analysis 17.7.1.1. Introduction 17.7.1.2. Market Analysis and Forecast by Market Taxonomy 17.7.1.2.1. By Services 17.7.1.2.2. By Product 17.7.1.2.3. By Company Size 17.7.1.2.4. By Scale of Operation 17.7.2. Hungary Market Analysis 17.7.2.1. Introduction 17.7.2.2. Market Analysis and Forecast by Market Taxonomy 17.7.2.2.1. By Services 17.7.2.2.2. By Product 17.7.2.2.3. By Company Size 17.7.2.2.4. By Scale of Operation 17.7.3. Russia Market Analysis 17.7.3.1. Introduction 17.7.3.2. Market Analysis and Forecast by Market Taxonomy 17.7.3.2.1. By Services 17.7.3.2.2. By Product 17.7.3.2.3. By Company Size 17.7.3.2.4. By Scale of Operation 18. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034 18.1. Introduction 18.2. Historical Market Size (US$ million) Trend Analysis by Market Taxonomy, 2019 to 2023 18.3. Current and Future Market Size (US$ million) Analysis and Forecast by Market Taxonomy, 2024 to 2034 18.3.1. By Country 18.3.1.1. Saudi Arabia 18.3.1.2. Türkiye 18.3.1.3. South Africa 18.3.1.4. Other African Union 18.3.1.5. Rest of Middle East and Africa 18.3.2. By Services 18.3.3. By Product 18.3.4. By Company Size 18.3.5. By Scale of Operation 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Services 18.4.3. By Product 18.4.4. By Company Size 18.4.5. By Scale of Operation 18.5. Market Trends 18.6. Drivers & Restraints Impact Analysis 18.7. Country-Wise Analysis 18.7.1. Saudi Arabia Market Analysis 18.7.1.1. Introduction 18.7.1.2. Market Analysis and Forecast by Market Taxonomy 18.7.1.2.1. By Services 18.7.1.2.2. By Product 18.7.1.2.3. By Company Size 18.7.1.2.4. By Scale of Operation 18.7.2. Türkiye Market Analysis 18.7.2.1. Introduction 18.7.2.2. Market Analysis and Forecast by Market Taxonomy 18.7.2.2.1. By Services 18.7.2.2.2. By Product 18.7.2.2.3. By Company Size 18.7.2.2.4. By Scale of Operation 18.7.3. South Africa Market Analysis 18.7.3.1. Introduction 18.7.3.2. Market Analysis and Forecast by Market Taxonomy 18.7.3.2.1. By Services 18.7.3.2.2. By Product 18.7.3.2.3. By Company Size 18.7.3.2.4. By Scale of Operation 18.7.4. Other African Union Market Analysis 18.7.4.1. Introduction 18.7.4.2. Market Analysis and Forecast by Market Taxonomy 18.7.4.2.1. By Services 18.7.4.2.2. By Product 18.7.4.2.3. By Inhalation Platform 19. Competition Analysis 19.1. Competition Dashboard 19.2. Top Devices CDMO’s Market Positioning 19.2.1. Current Market Scenario (2024) 19.2.2. Short Term Forecast (2025) 19.2.3. Long Tem Forecast (2034) 19.3. Market Share Assessment 19.4. CDMO Market Insights 19.5. Competition Deep Dive 19.5.1. Recipharm AB 19.5.1.1. Overview 19.5.1.2. Inhalation Platform Portfolio 19.5.1.3. Key Financials 19.5.1.4. SWOT Analysis 19.5.1.5. Key Developments 19.5.1.6. Sales Footprint 19.5.1.7. Strategy Overview 19.5.1.7.1. Marketing Strategy 19.5.1.7.2. Inhalation Platform Strategy 19.5.1.7.3. Channel Strategy 19.5.2. AptarGroup, Inc. 19.5.3. Hovione 19.5.4. Vectura Group Ltd. 19.5.5. Nemera 19.5.6. Kindeva 19.5.7. H&T Presspart 19.5.8. Sanner GmbH 19.5.9. Stevanato Group 19.5.10. Medspray 19.5.11. ICONOVO AB 19.5.12. Lonza 19.5.13. Gerresheimer AG 19.5.14. Catalent 19.5.15. Patheon N.V. (Thermo Fisher Scientific, Inc.) 19.5.16. Lubrizol Life Science 19.5.17. Enteris BioPharma 19.5.18. Cambrex Corporation 19.5.19. INKE 19.5.20. Piramal Pharma Limited 19.5.21. Lupin 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Inhalation CDMO Market
